| 0.74 -0.01 (-1.33%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.92 | 1-year : | 1.07 |
| Resists | First : | 0.79 | Second : | 0.92 |
| Pivot price | 0.69  |
|||
| Supports | First : | 0.66 | Second : | 0.58 |
| MAs | MA(5) : | 0.73 |
MA(20) : | 0.68 |
| MA(100) : | 0.63 |
MA(250) : | 1.12 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 84.6 |
D(3) : | 85.4 |
| RSI | RSI(14): 61.3 |
|||
| 52-week | High : | 1.96 | Low : | 0.54 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SYBX ] has closed below upper band by 21.6%. Bollinger Bands are 22.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.74 - 0.75 | 0.75 - 0.75 |
| Low: | 0.66 - 0.67 | 0.67 - 0.67 |
| Close: | 0.73 - 0.74 | 0.74 - 0.75 |
Operating as a clinical-stage biopharmaceutical enterprise, Synlogic, Inc. is dedicated to the creation and progression of synthetic biotic therapeutics aimed at addressing metabolic and immunological conditions across the United States. Its robust portfolio features multiple drug candidates: SYNB1618 and SYNB1934, both non-systemically absorbed and orally administered, are progressing through Phase II clinical trials for phenylketonuria. Another oral, non-systemic agent, SYNB1353, is designed to treat homocystinuria. Furthermore, SYNB8802, an orally taken, non-systemic compound, is currently in Phase I trials for managing enteric hyperoxaluria. Beyond oral treatments, the company is also developing SYNB1891, an intratumorally delivered synthetic biotic medicine undergoing Phase I investigation for solid tumors and lymphoma. Synlogic, Inc. has established partnerships with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks, Inc., and its main office is located in Cambridge, Massachusetts.
Mon, 18 May 2026
SYNLOGIC (SYBX) files Form 25 with Nasdaq to withdraw Common Stock listing - Stock Titan
Mon, 06 Apr 2026
Investor group offers $0.64 cash for Synlogic (SYBX) in take-private move - Stock Titan
Tue, 20 Jan 2026
Synlogic to Delist from Nasdaq and Move to OTC - TipRanks
Wed, 26 Nov 2025
Nasdaq notifies Synlogic of potential delisting over public shell status - Investing.com
Sat, 10 Feb 2024
Synlogic Announces Plan to Cease Operations and Reduce Its Workforce by More Than 90% - SynBioBeta
Wed, 16 Nov 2022
Gregg Beloff Net Worth (2026) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 22.6 (%) |
| Held by Institutions | 35.2 (%) |
| Shares Short | 10 (K) |
| Shares Short P.Month | 15 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -12.34 |
| PEG Ratio | 0 |
| Price to Book value | 0.73 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|